654
Participants
Start Date
Not specified
Study Completion Date
May 31, 1993
Zidovudine
Zalcitabine
Didanosine
Beth Israel Med. Ctr. (Mt. Sinai), New York
NY Univ. HIV/AIDS CRS, New York
Cornell University A2201, New York
Memorial Sloan-Kettering Cancer Ctr., New York
Univ. of Rochester ACTG CRS, Rochester
Hosp. of the Univ. of Pennsylvania CRS, Philadelphia
Unc Aids Crs, Chapel Hill
Case CRS, Cleveland
Univ. of Cincinnati CRS, Cincinnati
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis
Methodist Hosp. of Indiana, Indianapolis
Hennepin County Med. Ctr., Div. of Infectious Diseases, Minneapolis
University of Minnesota, ACTU, Minneapolis
Cook County Hosp. CORE Ctr., Chicago
Rush Univ. Med. Ctr. ACTG CRS, Chicago
Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr., Omaha
USC CRS, Los Angeles
Harbor-UCLA Med. Ctr. CRS, Torrance
Ucsd, Avrc Crs, San Diego
Stanford CRS, Palo Alto
Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu
University of Washington AIDS CRS, Seattle
Ucsf Aids Crs, San Francisco
Santa Clara Valley Med. Ctr., San Jose
San Mateo County AIDS Program, San Mateo
University of Colorado Hospital CRS, Aurora
Univ. of Miami AIDS CRS, Miami
Northwestern University CRS, Chicago
Univ. of Iowa Healthcare, Div. of Infectious Diseases, Iowa City
Beth Israel Deaconess - East Campus A0102 CRS, Boston
St. Louis ConnectCare, Infectious Diseases Clinic, St Louis
Washington U CRS, St Louis
The Ohio State Univ. AIDS CRS, Columbus
Mbeya Med. Research Program, Mbeya Referral Hosp. CRS, Mbeya
Massachusetts General Hospital ACTG CRS, Boston
Bmc Actg Crs, Boston
Puerto Rico-AIDS CRS, San Juan
Collaborators (2)
Bristol-Myers Squibb
INDUSTRY
Glaxo Wellcome
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH